419 related articles for article (PubMed ID: 36497266)
1. Natural Killer Cells in Chronic Lymphocytic Leukemia: Functional Impairment and Therapeutic Potential.
Yano M; Byrd JC; Muthusamy N
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497266
[TBL] [Abstract][Full Text] [Related]
2. NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications.
Sportoletti P; De Falco F; Del Papa B; Baldoni S; Guarente V; Marra A; Dorillo E; Rompietti C; Adamo FM; Ruggeri L; Di Ianni M; Rosati E
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206399
[TBL] [Abstract][Full Text] [Related]
3. Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia.
Hofland T; Eldering E; Kater AP; Tonino SH
Int J Mol Sci; 2019 Sep; 20(17):. PubMed ID: 31484424
[TBL] [Abstract][Full Text] [Related]
4. Current state of NK cell-mediated immunotherapy in chronic lymphocytic leukemia.
Wang ZH; Li W; Dong H; Han F
Front Oncol; 2022; 12():1077436. PubMed ID: 37078002
[TBL] [Abstract][Full Text] [Related]
5. Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy.
Guven H; Gilljam M; Chambers BJ; Ljunggren HG; Christensson B; Kimby E; Dilber MS
Leukemia; 2003 Oct; 17(10):1973-80. PubMed ID: 14513047
[TBL] [Abstract][Full Text] [Related]
6. Natural Killer Cell-Mediated Immunotherapy for Leukemia.
Allison M; Mathews J; Gilliland T; Mathew SO
Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159109
[TBL] [Abstract][Full Text] [Related]
7. BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia.
Sordo-Bahamonde C; Lorenzo-Herrero S; Gonzalez-Rodriguez AP; R Payer Á; González-García E; López-Soto A; Gonzalez S
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33917094
[TBL] [Abstract][Full Text] [Related]
8. DNA damage response and evasion from immunosurveillance in CLL: new options for NK cell-based immunotherapies.
Shatnyeva OM; Hansen HP; Reiners KS; Sauer M; Vyas M; von Strandmann EP
Front Genet; 2015; 6():11. PubMed ID: 25699074
[TBL] [Abstract][Full Text] [Related]
9. Tim-3 and PD-1 blocking cannot restore the functional properties of natural killer cells in early clinical stages of chronic lymphocytic leukemia: An
Astaneh M; Rezazadeh H; Hossein-Nataj H; Shekarriz R; Zaboli E; Shabani M; Asgarian-Omran H
J Cancer Res Ther; 2022; 18(3):704-711. PubMed ID: 35900543
[TBL] [Abstract][Full Text] [Related]
10. Specific features of T- and NK-cellular immunity in chronic lymphocytic leukemia.
Pochtar EV; Lugovskaya SA; Naumova EV; Dmitrieva EA; Kostin AI; Dolgov VV
Klin Lab Diagn; 2021 Jun; 66(6):345-352. PubMed ID: 34105910
[TBL] [Abstract][Full Text] [Related]
11. NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors.
MacFarlane AW; Jillab M; Smith MR; Alpaugh RK; Cole ME; Litwin S; Millenson MM; Al-Saleem T; Cohen AD; Campbell KS
Oncoimmunology; 2017; 6(7):e1330235. PubMed ID: 28811973
[TBL] [Abstract][Full Text] [Related]
12. Natural Killer Cell Hypo-responsiveness in Chronic Lymphocytic Leukemia can be Circumvented In Vitro by Adequate Activating Signaling.
Hofland T; Endstra S; Gomes CKP; de Boer R; de Weerdt I; Bobkov V; Riedl JA; Heukers R; Smit MJ; Eldering E; Levin MD; Kater AP; Tonino SH
Hemasphere; 2019 Dec; 3(6):e308. PubMed ID: 31976482
[TBL] [Abstract][Full Text] [Related]
13. LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia.
Sordo-Bahamonde C; Lorenzo-Herrero S; González-Rodríguez AP; Payer ÁR; González-García E; López-Soto A; Gonzalez S
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33925565
[TBL] [Abstract][Full Text] [Related]
14. Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia.
Villa-Álvarez M; Sordo-Bahamonde C; Lorenzo-Herrero S; Gonzalez-Rodriguez AP; Payer AR; Gonzalez-Garcia E; Villa-Álvarez MC; López-Soto A; Gonzalez S
Front Immunol; 2018; 9():2917. PubMed ID: 30619281
[TBL] [Abstract][Full Text] [Related]
15. T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword.
Vlachonikola E; Stamatopoulos K; Chatzidimitriou A
Front Immunol; 2020; 11():612244. PubMed ID: 33552073
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges.
Perutelli F; Jones R; Griggio V; Vitale C; Coscia M
Front Oncol; 2022; 12():837531. PubMed ID: 35265527
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia.
McWilliams EM; Mele JM; Cheney C; Timmerman EA; Fiazuddin F; Strattan EJ; Mo X; Byrd JC; Muthusamy N; Awan FT
Oncoimmunology; 2016; 5(10):e1226720. PubMed ID: 27853650
[TBL] [Abstract][Full Text] [Related]
19. Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells.
Herrera L; Santos S; Vesga MA; Anguita J; Martin-Ruiz I; Carrascosa T; Juan M; Eguizabal C
Sci Rep; 2019 Dec; 9(1):18729. PubMed ID: 31822751
[TBL] [Abstract][Full Text] [Related]
20. Discrepancy between phenotypic and functional features of natural killer T-lymphocytes in B-cell chronic lymphocytic leukaemia.
Foa R; Lauria F; Lusso P; Giubellino MC; Fierro MT; Ferrando ML; Raspadori D; Matera L
Br J Haematol; 1984 Nov; 58(3):509-16. PubMed ID: 6333890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
